Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

Merck’s stock showed a slight pulse this week, with a 0.41% daily rise and a 4.31% gain over five days, prompting cautious ...

The S&P 500 ended slightly higher on Monday (June 9), extending its gains for a second session, as markets reacted to renewed ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety ...